Book a meeting
DO-BO

How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?

Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.

This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you’re a health economist, market access leader, or data expert, this is a must-listen to improve cross-functional impact and efficiency.

Related

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

By

Stefan Walzer

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

By

Stefan Walzer

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]

What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

By

Stefan Walzer

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement. The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as […]